Graco (GGC) was upgraded to sector perform at RBC Capital. $81 price target. The company's earnings are proving to be more resilient, RBC said.
Valeant Pharmaceuticals (VRX) was downgraded to hold from buy at TD Securities. $110 price target. The company has withdrawn its 2016 earnings guidance, TD said.
This article was written by a staff member of TheStreet.